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Aims Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endoge-
nous fibrinolysis, which strongly relates to improved functional outcome. The impact of oral anticoagulants on en-
dogenous fibrinolysis is unknown. Our aim was to test the hypothesis that apixaban enhances endogenous fibrino-
lysis in non-valvular atrial fibrillation (NVAF).
...................................................................................................................................................................................................
Methods
and results
In a prospective cross-sectional analysis, we compared endogenous fibrinolysis in NVAF patients (n = 180) taking
aspirin, warfarin, or apixaban. In a prospective longitudinal study, patients were tested before and after apixaban
(n = 80). Endogenous fibrinolysis was assessed using the Global Thrombosis Test (GTT) and thromboelastography
(TEG). Endogenous fibrinolysis [measured by GTT lysis time (LT)] was shorter on apixaban compared with warfa-
rin or aspirin [median 1850 (IQR 1591–2300) vs. 2758 (2014–3502) vs. 2135 (1752–2463) s, P < 0.0001]. Among
TEG indices, a small but significant difference in clot lysis time (CLT) was observed [apixaban 60.0 (45.0–61.0) vs.
warfarin 61.0 (57.0–62.0) vs. aspirin 61.0 (59.0–61.0) min, P = 0.036]. Apixaban improved endogenous fibrinolysis
measured using the GTT [LT pre-treatment 2204 (1779–2738) vs. on-treatment 1882 (1607–2374) s, P = 0.0003],
but not by using TEG. Change in LT (DLT) with apixaban correlated with baseline LT (r = 0.77, P < 0.0001). There
was weak correlation between DLT and DCLT in response to apixaban (r = 0.28, P = 0.02) and between on-
apixaban LT and CLT (r = 0.25, P¼ 0.022).
...................................................................................................................................................................................................
Conclusion Apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment.
Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin.
Whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis,
compared to warfarin, merits further study.
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Introduction
Spontaneous fibrinolysis is an important defence mechanism against
downstream infarction following occlusive arterial thrombosis. In
patients with acute stroke, spontaneous arterial recanalization is ob-
served in 17–24% of patients and is strongly related to improved
functional outcomes. Importantly, ex vivo endogenous fibrinolysis has
been shown to be significantly impaired in patients with stroke com-
pared to normal volunteers.1 Impaired endogenous fibrinolysis has
also been shown to be marker of recurrent thrombotic risk in
patients with acute coronary syndrome2 and end-stage renal failure.3
Patients with atrial fibrillation (AF) frequently exhibit impaired en-
dogenous fibrinolysis and preliminary data indicate that this state
improves after successful restoration of sinus rhythm with radiofre-
quency ablation.4 A review of the importance of endogenous fibrino-
lysis in determining clinical outcomes concluded that global assays,
assessing proaggregatory, and fibrinolytic pathways, could aid in iden-
tifying impaired fibrinolysis as a potential target for pharmacological
modulation.3
Currently, there is no available oral pharmacotherapy to favour-
ably modulate fibrinolytic status where this is impaired. Beside the
use of plasminogen activators to achieve acute thrombolysis in the
setting of acute myocardial infarction and stroke, pharmacological
options to manipulate the fibrinolytic state are limited. Our prelimi-
nary data indicate that the non-vitamin K antagonist oral anticoagu-
lants (NOACs) may enhance endogenous fibrinolysis in patients with
AF, with significant effect observed only with apixaban.4 In our pilot
data in 20 patients, apixaban enhanced endogenous fibrinolysis, evi-
denced by a significant reduction in endogenous fibrinolysis time.
However, it is noteworthy that with all NOACs, there was a trend to
favourably enhancing endogenous fibrinolysis and perhaps if the sam-
ple size had been sufficiently large, a significant effect may have been
observed. Neither warfarin, nor aspirin or clopidogrel, have been
shown to enhance endogenous fibrinolysis.
Nevertheless, the impact of pharmacotherapy on the effectiveness
of the spontaneous endogenous fibrinolytic pathway has been diffi-
cult to measure, due to lack of available techniques. Factorial assays
such as plasminogen activator inhibitor 1, tissue plasminogen activa-
tor and thrombin activatable fibrinolysis inhibitor cannot provide a
reflection of the overall state of endogenous fibrinolysis.3 There are
currently two point-of-care techniques that provide a global assess-
ment of thrombus formation and fibrinolysis, namely thromboelas-
tography (TEG or ROTEM), which uses citrated or whole blood, and
the Global Thrombosis Test (GTT), using non-anticoagulated blood.
The determinants of the results of these global tests of fibrinolysis
are the thrombus properties (clot strength, determined by the thick-
ness, density, and pore size of fibrin strands) and the rate of
fibrinolysis.
We hypothesized that there was beneficial effect of apixaban on
endogenous fibrinolysis in patients with non-valvular atrial fibrillation
(NVAF). To test this hypothesis, we performed a cross-sectional
study of NVAF patients treated with apixaban, warfarin, or aspirin.
Second, we assessed the impact of initiating apixaban.
Methods
We conducted a prospective, observational (non-randomized) study in
200 stable outpatients with NVAF, approved by the National Research
Ethics Service and the UK Health Research Authority (ClinicalTrials.gov
identifier: NCT03199521). All subjects gave written informed consent
and the study was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice.
The study comprised two arms; a longitudinal arm (n = 80) and a
cross-sectional arm (n = 180), with 60 patients on apixaban taking part in
both. In the prospective longitudinal study, 80 patients with newly diag-
nosed NVAF were recruited, who were scheduled to start anticoagula-
tion with apixaban for thromboprophylaxis of stroke and systemic
embolism and who were studied before and during apixaban treatment.
In the cross-sectional study, 180 patients with known NVAF already
established on treatment with one of aspirin (n = 60), warfarin (n = 60) or
apixaban (n = 60) for thromboprophylaxis of stroke and systemic embo-
lism, were studied in an observational study, where drug allocation was
by physician choice, and not randomized.
The following exclusion criteria were applied: age <18 years; significant
hepatic or renal impairment likely to cause a bleeding diathesis; patients
taking antiplatelet or anticoagulant therapy (except for patients taking
part in the cross-sectional study), systemic steroids or immunosuppres-
sion; known active malignancy; bleeding diathesis; blood dyscrasia [plate-
lets <70  109/L, haemoglobin <80 g/L, international normalized ratio
(INR) >1.4; activated partial thromboplastin time (aPTT) more than twice
upper limit of normal; and leucocyte count <3.5  109/L, neutrophil
count <1  109/L); active alcohol; or substance abuse; those involved in
another investigational trial of a medicine or medical device; those unable
or unwilling to provide consent.
Antithrombotic therapy
The choice of oral antithrombotic therapy was decided by the clinical
care team. Apixaban was given at a dose of 5 mg b.i.d. (or 2.5 mg b.i.d. in
patients with two or more of the following: age >_80 years, weight <_60 kg,
and serum creatinine >_133 lmol/L). In the longitudinal study, blood sam-
ples were taken before (i.e. non-anticoagulated) and after patients were
established on uninterrupted apixaban treatment for at least 4 weeks. For
the cross-sectional study, blood samples were obtained after patients had
What’s new?
• Impaired endogenous fibrinolysis is a recently recognized risk
factor for adverse cardiovascular events.
• There are currently no known oral medications which can en-
hance endogenous fibrinolysis.
• In a prospective study of 240 patients with non-valvular atrial
fibrillation, we studied the effects of apixaban on endogenous
fibrinolytic status.
• We demonstrate that apixaban enhances endogenous fibrino-
lysis, with maximal effect in those with impaired fibrinolysis
pre-treatment. This is the first study showing favourable modu-
lation of endogenous fibrinolysis using an oral medication.
• In a cross-sectional study, apixaban-treated patients exhibited
more favourable fibrinolysis profile than patients taking warfa-
rin or aspirin.
• Future studies are needed to assess whether enhancing fibrino-
lysis with apixaban when this is impaired, might translate into a
reduction in ischaemic and thromboembolic events, and
whether patients with impaired fibrinolysis may derive greater
benefit from apixaban than warfarin or aspirin.
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been established on treatment for at least 4 weeks. Patients taking warfa-
rin were tested after at least three previous consecutive INR readings
within the therapeutic range (2.0–3.0).
Blood sampling
Venous blood samples were obtained from an antecubital vein using an
18-G butterfly cannula and a two-syringe technique. The first 5 mL was
used for routine blood tests and the second 10 mL used for assessment
of thrombotic status and apixaban levels measured using drug-specific cal-
ibrators (anti-Xa [FXa] level). Blood samples were taken 4–6 h after the
last dose of apixaban. Fasting was not required.
Assessment of thrombotic status including
endogenous fibrinolysis
Global thrombosis test
Thrombotic status was assessed using the point-of-care GTT
(Thromboquest Ltd, London, UK), which assesses overall thrombotic sta-
tus, including platelet reactivity, coagulation and endogenous (spontane-
ous) thrombolysis.2 The test was performed on native, non-
anticoagulated whole blood within 15 s of withdrawal. The instrument
assesses firstly the time taken to form an occlusive thrombus under high
shear, which is a marker of platelet reactivity (occlusion time, OT).
Shorter OT represents enhanced platelet reactivity. Following the arrest
of flow due to the formation of an occlusive platelet thrombus cross-
linked by fibrin strands. Following a short stabilization period, the instru-
ment records the time required to dissolve the thrombus formed in the
first phase, through endogenous fibrinolysis, which manifests in restart of
flow (lysis time, LT). Longer LTs represent less effective endogenous fibri-
nolysis. In addition, the GTT measures thrombus stability by measuring
the number of rebleeds (number of drops, D) after OT until the compete
occlusion and final arrest of flow. The intra-assay and inter-assay coeffi-
cients of variation (CV) for OT and LT were assessed in 10 subjects on
repeated sampling and also running samples in parallel.
Thromboelastography
Venous blood was also assessed with TEG (TEG 5000 Hemostasis
Analyser System, Haemonetics, Watford, UK). Two tests were per-
formed in parallel for each patient, one using non-citrated whole blood
tested immediately after withdrawal and one using non-citrated whole
blood with the addition of kaolin activator after four minutes, according
to the manufacturer’s instructions. The TEG assesses platelet-
independent clot formation, fibrinogen contribution to clot integrity (R,
K, A, MA, and TMA) as well as the primary fibrinolytic potential of the
clot (LY30, LY60, and CLT) (Table 3). The intra-assay and inter-assay CV
for all TEG parameters were assessed in 10 subjects on repeated sam-
pling and running samples in parallel for the whole blood alone and with
kaolin activator.
Apixaban (anti-FXa) levels
In patients taking apixaban, samples were taken for apixaban level at the
same time as blood draw for thrombotic status assessment. Apixaban
level was measured using HemosIL Liquid Heparin kit (Werfen UK,
Birchwood, Warrington, Cheshire, UK) on ACL TOP500 analyser using
drug-specific calibrators. Based on population pharmacokinetics studies
on patients taking apixaban 5 mg b.i.d. for stoke prevention in NVAF,
peak and trough levels of apixaban (measured as anti-FXa levels) have
been reported as 171 ng/mL (91–321) and 103 ng/mL (41–230), respec-
tively.5 Anti-FXa levels were assessed by an independent investigator
blinded to GTT and TEG results.
Study endpoints
The primary endpoint was the change in thrombotic status, in particular
endogenous fibrinolysis, in response to apixaban in the longitudinal study.
The secondary endpoint was a comparison of endogenous fibrinolysis in
patients established on different antithrombotic treatments (apixaban,
warfarin, and aspirin) in the cross-sectional study.
Sample size and statistical analysis
Results from our pilot study4 showed a 24% relative reduction in endoge-
nous fibrinolysis time with apixaban with a medium effect size (r = 0.4,
z = 2.763, P = 0.006). Using a two-tailed t test, we calculated that a sample
size of 78 patients would be required to detect a 24% relative reduction
with 90% power based on an effect size of 0.4 and a = 0.05 (longitudinal
study). For the cross-sectional study, it was assumed that endogenous fi-
brinolysis in patients taking warfarin and aspirin would be similar, based
on our earlier pilot showing no change in endogenous fibrinolysis in re-
sponse to warfarin.6 Assuming a one-tailed independent group compari-
son and an effect size of 0.4, a total of 180 patients were required to give
a = 0.05 to achieve 80% power.
Data are presented as mean ± standard deviation when normally dis-
tributed, or as median (interquartile range), when non-normally distrib-
uted. Dichotomous variables were compared using the v2 test. Paired
comparison between groups was evaluated with paired t-test and
Wilcoxon rank sum test. The analysis of variance or Kruskal–Wallis test
was used to assess differences between groups. To investigate the rela-
tionship between the change in fibrinolysis in response to apixaban and
baseline characteristics, univariate and multivariate regression models
were used. All variables were analysed using univariate regression; clini-
cally relevant parameters and those shown to be significant (P <_ 0.05)
were entered into the multivariate model. In a post hoc analysis, the mod-
el’s assumptions were tested and the residuals were normally distributed.
Regression models were used to illustrate the linear prediction between
change in LT (DLT) and baseline LT. Correlations were analysed using
Pearson’s and Spearman’s methods. Analyses were performed with Stata
version 15.1 (StataCorp, College Station, TX, USA).
Results
Between June 2017 and May 2018, 270 patients were screened and
200 patients recruited. Clinical characteristics of patients in the longi-
tudinal study are presented in Table 1 and those in the cross-
sectional study in Table 2. For the GTT, the intra-assay CV for OT
was 6% and for LT 8%, and the inter-assay CV was 7% for OT and 9%
for LT. The average intra-assay CV for TEG was 22% using native
blood and 20% for native blood with kaolin.
Effect of apixaban on thrombotic status
including endogenous fibrinolysis
Distributions of OT and LT pre- and during apixaban treatment are
shown in Figure 1. Compared to baseline, apixaban significantly pro-
longed OT (361± 112 vs. 463 ± 124 s, P < 0.0001). The number of
drops (D) did not change in response to apixaban treatment
(2.5± 1.7 vs. 3.1± 1.6, P = 0.173). There was moderate inverse corre-
lation between the change in OT in response to apixaban (DOT) and
baseline OT (r =0.4, P = 0.0002).
Compared to baseline, LT on apixaban was significantly shorter
[2204 (1779–2738) vs. 1882 (1607–2374) s, P = 0.0003]. There was
Effect of apixaban on endogenous fibrinolysis 1299
D
ow
nloaded from
 https://academ
ic.oup.com
/europace/article-abstract/21/9/1297/5522956 by Aalborg U
niversity Library user on 22 O
ctober 2019
....................................................................................................................................................................................................................
Table 1 Baseline clinical characteristics of patients in longitudinal study
Whole group
(n 5 80)
Baseline
LT 0–1500 (n 5 9)
Baseline LT
1501–3000 (n 5 53)
Baseline LT
3001–4500 (n 5 11)
Baseline LT
4501–6000 (n 5 7)
P-value
Age (years) 69.5 ± 13.6 70.2 ± 11.7 69.0 ± 15.0 67.3 ± 11.6 76.0 ± 7.0 0.675
Male 43 (54) 2 (22) 33 (62) 6 (55) 2 (29) 0.074
Weight (kg) 83.28 ± 26.64 67.57 ± 19.61 83.39 ± 25.78 95.57 ± 35.46 83.31 ± 18.11 0.211
Height (cm) 169.00 ± 14.21 163.77 ± 9.47 172.00 ± 11.35 160.90 ± 25.79 165.71 ± 7.86 0.085
BMI 27.93 ± 6.50 24.80 ± 5.25 27.68 ± 6.73 30.31 ± 5.96 30.00 ± 6.01 0.819
Current smoker 5 (6.3) 1 (11) 3 (5.6) 1 (9) 0 (0) 0.798
AF type
Paroxysmal 71 (88.8) 7 (78) 47 (89) 10 (90) 7 (100) 0.567
Persistent 9 (11.2) 2 (22) 6 (11) 1 (10) 0 (0) 0.512
Hypertension 48 (60) 4 (44) 30 (56) 9 (82) 5 (71) 0.293
Diabetes mellitus 11 (13.8) 2 (22) 7 (13) 2 (18) 0 (0) 0.603
Hyperlipidaemia 29 (36.3) 3 (33) 20 (38) 5 (45) 1 (14) 0.583
Prior CAD 5 (6.25) 0 (0) 4 (7.5) 1 (9) 0 (0) 0.712
Prior MI 2 (2.5) 0 (0) 1 (2) 1 (9) 0 (0) 0.484
Prior PCI 2 (2.5) 0 (0) 2 (3.7) 0 (0) 0 (0) 0.790
Renal impairment 3 (3.8) 1 (11) 2 (3.7) 0 (0) 0 (0) 0.562
Prior major bleeding 2 (2.5) 0 (0) 2 (3.75) 0 (0) 0 (0) 0.790
Prior CVA 3 (3.8) 0 (0) 3 (5.5) 0 (0) 0 (0) 0.662
LV impairment
None 72 (90) 7 (77) 47 (89) 11 (100) 9 (100) 0.308
Mild 5 (6) 1 (11) 3 (5.5) 0 (0) 0 (0) 0.636
Moderate 2 (2.5) 1 (11) 1 (1.8) 0 (0) 0 (0) 0.350
Severe 1 (1.5) 0 (0) 2 (3.7) 0 (0) 0 (0) 0.790
CHA2DS2VASc score 3 (1–4) 3 (2–3) 2 (1–4) 3 (2–3) 3 (2–3) 0.193
HASBLED score 1 (1–1) 1 (1–1) 1 (1–1) 1 (0–1) 1 (1–2) 0.128
Concomitant medication
Statin 29 (36) 4 (44) 20 (38) 4 (36) 1 (14) 0.621
Beta blocker 21 (26) 1 (11) 14 (26) 5 (45) 1 (14) 0.298
CCB blocker 23 (28.75) 2 (22) 12 (23) 5 (45) 4 (57) 0.144
PPI 17 (21.25) 2 (22) 11 (21) 2 (18) 2 (29) 0.960
Metformin 6 (7.5) 1 (11) 4 (7.5) 1 (9) 0 (0) 0.855
Baseline blood tests
Haemoglobin (g/L) 138 ± 19 127 ± 18 139 ± 20 144 ± 9 134 ± 19 0.118
Haematocrit (%) 41 ± 5 38 ± 5 41 ± 5 43 ± 3 40 ± 7 0.151
Platelet count (109/L) 257 ± 85 296 ± 76 248 ± 85 249 ± 28 281 ± 141 0.259
White cell count (109/L) 8.7 ± 2.7 7.7±1.8 8.8 ± 2.4 8.4 ± 3.2 9.1 ± 5.6 0.583
eGFR 72 ± 16 74 ± 21 71 ± 16 77 ± 14 65 ± 11 0.261
Fibrinogen (g/L) 4.5 ± 1.5 3.6 ± 0.5 4.4 ± 1.5 4.8 ± 0.9 5.8 ± 1.7 0.122
PT (s) 12.0 ± 1.4 11.5 ± 1.3 12.0 ± 1.4 12.1 ± 1.7 11.5 ± 0.9 0.748
aPTT (s) 28.6 ± 3.3 28.6 ± 4.0 28.0 ± 2.2 31.0 ± 6.2 29.2 ± 3.0 0.411
CRP (mg/L) 4.8 ± 6.6 2.3 ± 2.2 5.4 ± 7.7 3.2 ± 2.8 7 ± 5 0.182
OT at baseline (s) 361 ± 112 377 ± 126 360 ± 110 376 ± 109 324 ± 130 0.740
LT at baseline (s) 2204 (1779–2738) 1425 (1350–1454) 2114 (1800–2347) 3427 (3099–3667) 5166 (4843–6000) <0.001
OT on treatment (s) 463 ± 124 501 ± 98.4 452 ± 118 542 ± 151 376 ± 88 0.038
LT on treatment (s) 1882 (1607–2374) 1367 (1206–1607) 1866 (1631–2312) 2322 (1975–3345) 2707 (1710–3285) <0.001
Values are presented as mean ± SD or median (IQR) and n (%). Renal impairment defined as eGFR <60; AF type; left ventricular function classification: mild 45–55% ejection
fraction, moderate 35–45% ejection fraction, and severe <35% ejection fraction. CHA2DS2VASc score in AF and HAS-BLED bleeding risk. Normal values: haemoglobin 130–
180 g/L in males and 115–165 g/L in females; haematocrit 40–52% in males and 36–47% in females; platelet count 150–400  109/L; white cell count 4–11  109/L; eGFR >60; fi-
brinogen 1.8–5.4 g/L; PT 11–13.5 s; aPTT 25–35 s; and CRP 0–5 mg/L.
Statistically significant values P < 0.05 are set in bold.
AF, atrial fibrillation; aPTT, activated partial thromboplastin time; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CRP, C-reactive protein;
CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LT, lysis time; MI, myocardial infarction; PCI, percutaneous coronary inter-
vention; PPI, proton pump inhibitor; SD, standard deviation.
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Table 2 Baseline clinical characteristics of patients in cross-sectional study
Whole group
(n 5 180)
Apixaban
(n 5 60)
Warfarin
(n 5 60)
Aspirin
(n 5 60)
P-value
Age (years) 73.8 ± 12.1 69.6 ± 13.4 74.6 ± 9.7 77.1 ± 12.0 0.248
Male 105 (58) 33 (55) 35 (58) 37 (62) 0.636
Weight (kg) 82.37 ± 21.22 83.70 ± 27.15 83.62 ± 18.01 79.80 ± 17.16 0.573
Height (cm) 169.48 ± 11.87 168.45 ± 15.68 171.11 ± 8.83 168.88 ± 9.97 0.567
BMI 28.00 ± 5.60 28.25 ± 7.08 28.13 ± 5.03 27.60 ± 4.35 0.652
Current smoker 11 (6) 5 (8) 4 (7) 2 (3) 0.598
AF type
Paroxysmal 138 (76) 54 (90) 35 (60) 48 (80) 0.001
Persistent 28 (16) 6 (10) 12 (20) 10 (17) 0.115
Hypertension 122 (68) 37 (62) 42 (70) 43 (70) 0.454
Diabetes mellitus 33 (18) 9 (15) 12 (20) 12 (20) 0.716
Hyperlipidaemia 99 (55) 26 (43) 31 (52) 42 (70) 0.011
Prior CAD 44 (24) 3 (5) 20 (33) 21 (35) <0.001
Prior MI 20 (11) 2 (3) 10 (17) 8 (13) 0.054
Prior PCI 15 (8) 2 (3) 9 (15) 4 (6) 0.059
Renal impairment 18 (10) 2 (3) 7 (12) 9 (15) 0.090
Prior major bleeding 7 (4) 2 (3) 5 (8) 0 (0) 0.059
Prior CVA 25 (14) 3 (5) 11 (18) 11 (18) 0.051
Prior LV impairment
None 150 (83) 54 (90) 47 (78) 49 (82) 0.090
Mild 15 (8) 3 (5) 6 (10) 6 (10) 0.253
Moderate 9 (5) 1 (2) 6 (10) 2 (3) 0.147
Severe 6 (4) 2 (3) 1 (2) 3 (5) 1.000
CHA2DS2VASc score 3 (2–4) 3 (1–4) 4 (2–5) 4 (3–5) 0.945
HASBLED score 1 (1–2) 1 (1–1) 1 (1–2) 1 (1–2) 0.388
Concomitant medication
Statin 107 (59) 25 (42) 40 (66) 42 (70) 0.003
Beta blocker 92 (51) 15 (25) 11 (18) 15 (25) <0.001
CCB 44 (24) 18 (30) 11 (18) 15 (25) 0.329
PPI 68 (38) 13 (22) 26 (43) 29 (48) 0.006
Metformin 19 (11) 5 (8) 7 (12) 7 (12) 0.790
Baseline blood tests
Haemoglobin (g/L) 134 ± 17 138 ± 18 132 ± 15 133 ± 16 0.428
Haematocrit (%) 40 ± 5 41 ± 5 40 ± 4 40 ± 4 0.743
Platelet count (109/L) 227 ± 72 235 ± 55 215 ± 85 229 ± 72 0.052
White cell count (109/L) 7.6 ± 2.0 7.9 ± 2.1 7.1 ± 1.9 7.7 ± 2.0 0.093
eGFR 67 ± 16 70 ± 16 66 ± 16 65 ± 17 0.139
Fibrinogen (g/L) 4.5 ± 1.1 4.4 ± 1.4 4.5 ± 1.0 4.5 ± 0.9 0.402
PT (s) 17.7 ± 9.1 12.0 ± 1.4 29.5 ± 6.7 12.3 ± 2.3 <0.001
aPTT (s) 32.0 ± 7.3 28.3 ± 3.3 38.8 ± 7.3 29.0 ± 5.4 <0.001
CRP (mg/L) 5.5 ± 10.6 4.7 ± 6.4 4.0 ± 3.6 7.4 ± 16 0.872
Values are presented as mean ± SD or median (IQR) and n (%). Renal impairment defined as eGFR <60; AF type; left ventricular function classification: mild 45–55% ejection
fraction, moderate 35–45% ejection fraction, and severe <35% ejection fraction. CHA2DS2VASc score in AF and HAS-BLED bleeding risk. Normal values: haemoglobin 130–
180 g/L in males and 115–165 g/L in females; haematocrit 40–52% in males and 36–47% in females; platelet count 150–400  109/L; white cell count 4–11  109/L; eGFR >60; fi-
brinogen 1.8–5.4 g/L; PT 11–13.5 s; aPTT 25–35 s; and CRP 0–5 mg/L.
Statistically significant values P < 0.05 are set in bold.
AF, atrial fibrillation; aPTT, activated partial thromboplastin time; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CRP, C-reactive protein;
CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention; PPI,
proton pump inhibitor; SD, standard deviation.
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no correlation between baseline OT and baseline LT (P = 0.740) or
between on-treatment OT and on-treatment LT (P = 0.241).
Apixaban did not alter TEG indices, except for a small reduction in
the rate of clot formation with kaolin (68.4 vs. 67, P = 0.026)
(Tables 3 and 4).
Baseline OT and LT did not correlate with any of the baseline TEG
indices with or without kaolin. In particular, baseline fibrinolysis as-
sessment (LT) with the GTT did not correlate with any of the base-
line TEG indices of fibrinolysis (LY30, LY60, and CLT). On-treatment
OT did not correlate with any on-treatment TEG indices. There was
a significant correlation between DOT and the change in reaction
time (R) with kaolin in response to apixaban (r = 0.54, P < 0.0001).
There was a weak correlation between on-treatment LT in GTT cor-
related with clot lysis time (CLT) in the TEG (r = 0.25, P = 0.022).
There was weak correlation between DLT and the change in kaolin
CLT (DCLT) in response to apixaban (r = 0.28, P = 0.02).
Magnitude of effect of apixaban in
relation to baseline fibrinolysis
The change in LT in response to apixaban (DLT) correlated closely
with baseline LT (r = 0.77, P < 0.0001). The magnitude of effect of
apixaban on reducing LT was greatest in those with the longest LT at
baseline (Figure 2). Patients on apixaban were grouped into quartiles
based on baseline LT to assess the magnitude of change in LT with
apixaban (Table 1). The DLT between the four groups was signifi-
cantly different (P < 0.0001).
Cross-sectional comparisons of apixaban,
warfarin, and aspirin
Measures of thrombotic status assessed with GTT and TEG are
shown in Table 5. LT was significantly lower in patients taking apixa-
ban than other medications. From the TEG indices, only native CLT
was significantly lower in the apixaban group compared to patients
on warfarin and aspirin. Multivariable regression models were applied
to account for baseline differences in the three groups. After ac-
counting for these variables (Table 2), both OT and LT remained sig-
nificantly different between the apixaban and the warfarin arms
(P < 0.0001).
Relationship of thrombotic effect to
apixaban levels
Apixaban levels in patients taking 5 mg b.i.d. was Cmax 152.9 ng/mL
(32.9–317.9 ng/mL), and in patients taking the 2.5 mg b.i.d. dose was
Cmax 125.85 ng/mL (40.6–344.6 ng/mL). Apixaban levels correlated
weakly with OT on apixaban (r = 0.27, P = 0.022) but not with LT.
There were no significant relationships between apixaban levels
and TEG parameters.
Discussion
In this study, our principal findings are as follow: (i) apixaban signifi-
cantly improved endogenous fibrinolysis, and the effect of apixaban
was greatest in those patients with the longest LT at baseline; and (ii)
in comparison to patients on warfarin or aspirin, patients taking apixa-
ban exhibited more rapid (more effective) endogenous fibrinolysis.
These observations may have clinical relevance, given that effec-
tiveness of endogenous fibrinolysis is an important determinant of
the clinical outcome of a thrombotic stimulus. Whether apixaban
may confer additional thrombotic risk reduction in NVAF patients
who have impaired fibrinolysis, compared to warfarin, requires fur-
ther study. Importantly, the finding that apixaban-treated patients ex-
hibit more favourable fibrinolysis profiles than those taking warfarin
or aspirin does not mean that apixaban by itself exhibits a more
favourable fibrinolysis profile as compared to aspirin and warfarin.
In our current study, 23% of patients with NVAF had significantly
prolonged LT before the start of anticoagulation (defined as baseline
LT >3000 s, based on prior data).3 Such impaired endogenous fibri-
nolysis in patients with acute coronary syndromes has been associ-
ated with increased risk of cardiovascular death and recurrent MI.2,3,5
Dual antiplatelet therapy post-ACS did not appear to reduce LT. The
average 15% reduction in fibrinolysis time with apixaban seen here is
potentially clinically significant, but even greater effect, up to 48% re-
duction in LT was seen in those with the most impaired fibrinolysis at
baseline. If apixaban were to exert similar reduction in LT in patients
with ACS, as that observed here in NVAF, that would be expected to
reduce the risk of major adverse cardiovascular event in those with
prolonged LT at baseline. Our observations suggest that further
study in controlled trials could investigate whether apixaban may
confer additional thrombotic risk reduction in NVAF patients with
impaired fibrinolysis, compared to warfarin.
The effect of improving fibrinolytic status with apixaban appears
not to be simply an anticoagulant effect, since patients on apixaban
had more rapid fibrinolysis than patients therapeutically anticoagu-
lated with warfarin, and there was no relation between apixaban
Table 3 TEG indices
R (min) Measures the time from the start of a sample run until
the first significant level of detectable clot formation.
R reduces in hypercoagulable conditions
K (min) Measures the time from R until a fixed level of clot
strength is reached. K is shortened in hypercoagu-
lable conditions.
Angle Represents the rate of clot formation and reflects fi-
brinogen activity. Angle relates to K. Both represent
the rate of clot formation. Angle is larger in hyper-
coagulable conditions
MA (mm) Represents whole clot strength and reflects many
aspects of clot formation including platelet number
and function as well as the fibrin contribution to clot
strength. MA is larger by hypercoagulable conditions
LY30 (%) Represents the percentage of clot which has lysed after
30 min of MA
LY60 (%) Represents the percentage of clot which has lysed after
60 min of MA
TMA (min) Measures the time to form maximum clot strength
CLT (min) Measures the time to 2 mm amplitude reduction from
MA
CLT, clot lysis time; K, kinetics; MA, maximum amplitude; R, reaction time; TEG,
thromboelastography; TMA, time to maximum amplitude.
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levels and LT. Apixaban levels in our study were similar to those pre-
viously reported5 and are known to correlate closely with anti-FXa
activity. In the ARISTOTLE trial, apixaban was as effective as warfarin
in reducing the risk of ischaemic stroke and systemic embolism in
NVAF, whilst the AVERROES study showed that apixaban was supe-
rior to aspirin.7 Both ARISTOTLE and AVERROES suggest a greater
benefit of apixaban, compared to warfarin, in reducing ischaemic
stroke and systemic embolism in patients with CHADS2 score >_3
than in patients with lower CHADS2 scores, suggesting apixaban may
have additional advantages in the highest risk patients. Although in
the ARISTOTLE trial comparing apixaban with warfarin in NVAF, the
secondary endpoint of combined ischaemic or uncertain type (not
clearly haemorrhagic or ischaemic) stroke was non-significantly dif-
ferent with both anticoagulants,8 a subgroup analysis of patients with
previous stroke or transient ischaemic attack showed the rate of
stroke or systemic embolism was significantly lower with apixaban
than with warfarin, suggesting that the absolute benefits of apixaban
might be even greater in high-risk patients.6 In the largest real-world
retrospective analysis of 77 000 patients with NVAF, apixaban use
was associated with significantly lower risk of stroke and systemic
embolism than warfarin.9
Apixaban is a direct inhibitor of free and clot- or prothro
mbinase-bound FXa, thereby prevents thrombin generation.
Thrombin is not only a key protein in fibrin clot formation, but
also the most potent activator of platelet aggregation in vivo10 and
an important determinant of the strength and stability of the fibrin
clot and its resistance to fibrinolysis.11 Apart from reduced
thrombin generation, FXa inhibition with apixaban might also im-
pact platelet haemostasis by blocking the direct effects of FXa via
protease activator receptor signalling.10
35A
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Figure 1 Effect of apixaban on occlusion time and lysis time. (A) Distribution of OT before and after apixaban treatment. (B) Distribution of LT be-
fore and after apixaban treatment. Apixaban significantly prolonged OT as evidenced by rightward shift (reduction in platelet reactivity). LT was signif-
icantly reduced as evidenced by leftward shift (representing faster lysis). LT, lysis time; OT, occlusion time.
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Nevertheless, studies assessing the effect of FX inhibition on plate-
let reactivity are few, but appear to show consistency in reduction of
tissue-factor/platelet-dependent thrombin generation and thrombus
formation. Blood spiked with rivaroxaban ex vivo showed reduced
platelet aggregation induced by tissue factor and to a lesser extent
induced by thrombin.12,13 Even at the very low dose of 2.5 mg b.i.d.,
rivaroxaban reduced platelet-dependent thrombin generation and
coagulation-dependent thrombus-formation in patients treated with
aspirin plus P2Y12 inhibitor, whereas pure platelet-dependent throm-
bus formation was not affected.14 Indeed, FXa inhibition appears to
have no significant effect on platelets14 including in response to aden-
osine diphosphate, collagen, thrombin receptor-activating peptide, or
arachidonic acid.15 Apixaban may therefore favourably enhance en-
dogenous fibrinolysis through reduction in platelet-dependent and
non-platelet-dependent thrombin generation, which directly impact
on the structure and stability of the thrombus and its resistance to
fibrinolysis.
The benefit of apixaban on endogenous fibrinolysis was only ob-
served with the GTT and not with TEG. The fundamental difference
between these techniques is that the GTT employs high shear to
stimulate thrombus formation resulting in platelet activation and
thrombin generation, whereas TEG is a haemostatic assay that meas-
ures the global viscoelastic properties of whole blood clot formation
under low shear. This results in significant differences in the clot
formed and therefore, also in what the ‘lysis’ assays measure. The
GTT assesses the lysis and stability of a platelet thrombus, whereas in
the TEG it reflects clot lysis. The GTT is particularly well-adapted to
investigate the role of thrombin inhibitors such as NOACs, primarily
because thrombin generation from shear-activated platelets and fi-
brin stabilization of the initial platelet aggregates play a major role in
determining the measured OT,3 whereas platelet-dependent throm-
bin generation is much less likely at the low shear rates in the TEG.
Nevertheless, the effect of NOACs on TEG parameters is conten-
tious. Whilst some small studies reported that apixaban had minimal
effect on TEG parameters, and that for the patients on apixaban,
mean R value was within reference range representative of a normal
population,16 others have shown that spiking of blood with apixaban
in vitro increased R time and time to maximal thrombus growth and
coagulation,17 prolonged clotting time and time to maximum
.................................................................................................
Table 4 Difference in GTTand TEG parameters in
response to apixaban
Baseline
(n 5 80)
Apixaban
(n 5 80)
P-value
OT (s) 361 ± 112 463 ± 124 <0.0001
LT (s) 2204 (1779–2738) 1882 (1607–2374) 0.0003
R (min) native 7.8 (5.4–11.4) 8.9 (6.1–12.2) 0.398
R (min) kaolin 4.2 (2.6–5.6) 4.8 (3.2–6.3) 0.159
K (min) native 3.6 (2.6–5.8) 4.2 (3.0–7.2) 0.096
K (min) kaolin 1.4 (1.1–2.2) 1.7 (1.4–2.3) 0.113
Angle (

) native 43.0 (39.0–47.0) 42.0 (38.0–45.0) 0.552
Angle (

) kaolin 68.4 (65.0–72.0) 67.0 (58.0–70.0) 0.026
MA (mm) native 34.5 (27.3–48.3) 34.6 (29.6–49.8) 0.535
MA (mm) kaolin 21.0 (17.8–25.0) 23.3 (20.0–25.9) 0.068
LY30 (%) native 0.1 (0.0–3.1) 0.0 (0.0–0.4) 0.276
LY30 (%) kaolin 1.9 (0.3–5.4) 0.4 (0.0–2.0) 0.066
LY60 (%) native 1.4 (0.0–5.8) 0.5 (0.0–3.0) 0.405
LY60 (%) kaolin 4.2 (1.9–9.9) 2.6 (1.0–4.6) 0.067
TMA (min) native 34.5 (27.3–48.3) 34.6 (29.6–49.8) 0.535
TMA (min) kaolin 21.0 (17.8–25.0) 23.3 (20.0–25.9) 0.068
CLT (min) native 60.6 (59.4–61.5) 60.15 (57.7–61.2) 0.155
CLT (min) kaolin 60.8 (59.5–61.7) 60.8 (59.7–61.5) 0.780
Statistically significant values P < 0.05 are set in bold.
CLT, clot lysis time; GTT, Global Thrombosis Test; K, kinetics; LT, lysis time; MA,
maximum amplitude; OT, occlusion time; R, reaction time; TEG, thromboelastog-
raphy; TMA, time to maximum amplitude.
7000
*
* *
6000
5000
4000
3000LT
 (
se
c)
2000
1000
0-1500 1501-3000 3001-4500
Baseline LT (sec)
4501-6000
0
Baseline
On treatment
Figure 2 Effect of apixaban on lysis time according to baseline LT. The effect of apixaban on LT was particularly marked in patients with longest
baseline LT. *P = 0.040, **P = 0.018. LT, lysis time.
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velocity.18 In the largest study assessing patients with NVAF with
TEG, patients taking NOAC developed clot that was quicker to lyse
than patients taking warfarin, and the rate of clot dissolution was
faster in those on apixaban than in rivaroxaban, with 11 of 16 TEG in-
dices showing a difference between those on aspirin, warfarin, or a
NOAC.19
Clinical implications
Our finding that that apixaban significantly improves endogenous fi-
brinolysis, particularly in patients with the longest LT at baseline, is
significant and may be clinically important. The current data indicate
that apixaban may have additional advantages over vitamin K antago-
nist (VKA) or aspirin in patients with impaired endogenous fibrinoly-
sis, although since we did not assess patients pre- and post-VKA or
aspirin, we cannot be sure of the relative effects of apixaban on fibri-
nolysis compared to VKA or aspirin.
Our findings support the signals from clinical trials, showing that
apixaban (rather than VKA or aspirin) may have additional advantages
in high-risk patients. Our data suggest that patients with impaired fi-
brinolysis may benefit more from apixaban to improve fibrinolysis,
than warfarin. Future studies are required to confirm whether
patients with NVAF and impaired fibrinolysis are at increased risk of
ischaemic stroke and systemic embolism, than those with effective fi-
brinolysis. If this is confirmed in large prospective studies, then
patients with NVAF and impaired fibrinolysis may gain additional ben-
efits from treatment with apixaban to favourably modulate endoge-
nous fibrinolysis, than from VKA or aspirin.
Whether enhancing endogenous fibrinolysis with apixaban when
this is impaired in patients with NVAF or even in acute coronary
syndromes, can translate into a reduction in ischaemic events, and
whether patients with prolonged LT derive greater benefit from apix-
aban than warfarin or other NOAC, requires further study.
Limitations
The main limitations of our study are the non-randomized, observa-
tional study design, and the relatively small number of participants.
The baseline LT in patients subsequently treated with apixaban was
not uniform and therefore a greater effect of apixaban on LT may
have been observed had we included more patients with impaired fi-
brinolysis at baseline. In the cross-sectional study, there were differ-
ences in clinical characteristics between the groups. Since fibrinolysis
was not assessed before aspirin or warfarin treatment, we do not
know the absolute magnitude of effect of these drugs on fibrinolysis,
which may confound conclusion drawn about the observed shorter
LT in patients on apixaban than on warfarin or aspirin. However, in
contemporary clinical practice, few patients in the UK with NVAF are
being started on VKA, and therefore, it would not have been logisti-
cally easy to compare patients pre- and post-VKA. Furthermore,
whilst compliance was assessed in the apixaban and warfarin arms, it
was not assessed in patients taking aspirin.
Conclusion
In conclusion, apixaban enhances endogenous fibrinolysis, with maxi-
mal effect in those with impaired fibrinolysis pre-treatment.
Apixaban-treated patients exhibit more favourable fibrinolysis pro-
files than those taking warfarin or aspirin. Whether apixaban may
....................................................................................................................................................................................................................
Table 5 Thrombotic parameters in patients taking apixaban, warfarin and aspirin
Apixaban
(n 5 60)
Warfarin
(n 5 60)
Aspirin
(n 5 60)
Three group
comparison
P-value
Apixaban vs.
warfarin 1
aspirin P-value
Apixaban 1
warfarin vs.
aspirin P-value
Apixaban vs.
warfarin
P-value
OT (s) 463 ± 131 589 ± 154 430 ± 121 0.126 0.054 0.025 <0.0001
LT (s) 1850 (1591–2300) 2758 (2014–3502) 2135 (1752–2463) 0.0001 <0.0001 0.465 <0.0001
R (min) native 8.8 (5.7–12.3) 13.0 (8.7–17.8) 8.8 (6.0–12.2) 0.001 0.059 0.067 0.0007
R (min) kaolin 4.7 (3.0–6.8) 6.5 (4.9–10.4) 3.0 (2.0–5.0) 0.0001 0.843 0.0002 0.006
K (min) native 4.4 (3.0–7.2) 5.4 (3.4–7.5) 4.0 (2.6–6.1) 0.076 0.954 0.0517 0.212
K (min) kaolin 1.7 (1.4–2.2) 2.0 (1.5–2.7) 1.5 (1.2–2.7) 0.152 0.789 0.0367 0.265
Angle (

) native 45.3 (30.7–52.1) 33.0 (26.2–47.9) 46.0 (33.0–59.0) 0.009 0.793 0.011 0.050
Angle (

) kaolin 70.0 (57.0–69.0) 61.0 (47.0–69.0) 67.3 (60.0–72.0) 0.152 0.839 0.084 0.265
MA (mm) native 70.0 (64.0–76.0) 69.0 (56.0–75.0) 69.0 (62.0–75.0) 0.673 0.386 0.830 0.347
MA (mm) kaolin 76.0 (72.0–80.0) 75.0 (72.0–79.0) 75.0 (73.0–79.0) 0.872 0.632 0.819 0.703
LY30 (%) native 0.0 (0.0–0.9) 0.0 (0.0–1.3) 0.0 (0.0–1.1) 0.841 0.810 0.744 0.980
LY30 (%) kaolin 0.4 (0.0–2.0) 0.6 (0.0–3.9) 1.2 (0.3–2.4) 0.872 0.264 0.293 0.520
LY60 (%) native 0.6 (0.0–3.1) 0.5 (0.0–5.6) 1.3 (0.1–4.7) 0.744 0.598 0.542 0.993
LY60 (%) kaolin 2.6 (1.0–5.0) 3.0 (1.0–9.5) 4.2 (2.1–5.9) 0.588 0.321 0.388 0.532
TMA (min) native 35.0 (30.0–50.0) 37.0 (32.0–49.0) 32.0 (26.0–43.0) 0.064 0.874 0.037 0.253
TMA (min) kaolin 24.0 (20.0–26.0) 26.0 (22.0–30.0 21.0 (16.0–23.0) 0.001 0.798 0.001 0.0511
CLT (min) native 60.0 (45.0–61.0) 61.0 (57.0–62.0) 61.0 (59.0–61.0) 0.036 0.011 0.100 0.055
CLT (min) kaolin 61.0 (60.0–62.0) 61.0 (60.0–62.0) 60.8 (60.4–61.4) 0.998 0.956 0.889 0.883
Statistically significant values P < 0.05 are set in bold.
CLT, clot lysis time; LT, lysis time; MA, maximal amplitude; OT, occlusion time; R, reaction time; TMA, time to maximal amplitude.
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confer additional thrombotic risk reduction in NVAF patients with
impaired fibrinolysis, compared to warfarin, merits further study.
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